guest ::
| Home > Publications database > Exploring Arylidene–Indolinone Ligands of Autophagy Proteins LC3B and GABARAP > print |
| Home > Publications database > Exploring Arylidene–Indolinone Ligands of Autophagy Proteins LC3B and GABARAP > print |
| 001 | 1044128 | ||
| 005 | 20250912110138.0 | ||
| 024 | 7 | _ | |a 10.1021/acsmedchemlett.4c00517 |2 doi |
| 024 | 7 | _ | |a 10.34734/FZJ-2025-03035 |2 datacite_doi |
| 024 | 7 | _ | |a 39967642 |2 pmid |
| 024 | 7 | _ | |a WOS:001390582400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2025-03035 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Leveille, Alexandria N. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Exploring Arylidene–Indolinone Ligands of Autophagy Proteins LC3B and GABARAP |
| 260 | _ | _ | |a Washington, DC |c 2025 |b ACS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1756275409_9345 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We report the first structure–activity studies of arylidene–indolinone compound GW5074, which was reported as a ligand of autophagy-related protein LC3B. The literature has conflicting information on the binding affinity of this compound, and there is some debate regarding its use as a component of autophagy-dependent degrader compounds. We developed an AlphaScreen assay to measure competitive inhibition of the binding of known peptide ligands to LC3B and its paralog GABARAP. Eighteen analogs were synthesized and tested against both proteins. Inhibitory potencies were found to be in the mid- to high-micromolar range. 2D-NMR data revealed the binding site on GABARAP as hydrophobic pocket 1, where native peptide ligands bind with an aromatic side chain. Our results suggest that GW5074 binds LC3B and GABARAP with micromolar affinity. These affinities could support further exploration in targeted protein degradation, but only if off-target effects and poor solubility can be appropriately addressed. |
| 536 | _ | _ | |a 5241 - Molecular Information Processing in Cellular Systems (POF4-524) |0 G:(DE-HGF)POF4-5241 |c POF4-524 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Schwarzrock, Thomas |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Brown, Hawley |0 0009-0001-9855-5877 |b 2 |
| 700 | 1 | _ | |a True, Bennett |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Plasencia, Joanet |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Neudecker, Philipp |0 P:(DE-Juel1)144510 |b 5 |
| 700 | 1 | _ | |a Üffing, Alina |0 P:(DE-Juel1)181095 |b 6 |
| 700 | 1 | _ | |a Weiergräber, Oliver H. |0 P:(DE-Juel1)131988 |b 7 |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 8 |
| 700 | 1 | _ | |a Kritzer, Joshua A. |0 0000-0003-2878-6781 |b 9 |e Corresponding author |
| 773 | _ | _ | |a 10.1021/acsmedchemlett.4c00517 |g Vol. 16, no. 2, p. 271 - 277 |0 PERI:(DE-600)2532386-6 |n 2 |p 271 - 277 |t ACS medicinal chemistry letters |v 16 |y 2025 |x 1948-5875 |
| 856 | 4 | _ | |y Published on 2025-01-06. Available in OpenAccess from 2026-01-06. |u https://juser.fz-juelich.de/record/1044128/files/2024_1125_Leveille_SI.pdf |
| 856 | 4 | _ | |y Published on 2025-01-06. Available in OpenAccess from 2026-01-06. |u https://juser.fz-juelich.de/record/1044128/files/2024_1217_leveille.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:1044128 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)144510 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)181095 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131988 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-524 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Molecular and Cellular Information Processing |9 G:(DE-HGF)POF4-5241 |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACS MED CHEM LETT : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1210 |2 StatID |b Index Chemicus |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1200 |2 StatID |b Chemical Reactions |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IBI-7-20200312 |k IBI-7 |l Strukturbiochemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|